Weekly Vaccine Digest 3/31

County of Los Angeles, California sent this bulletin at 03/31/2023 03:22 PM PDT

Weekly Vaccine Digest 3/31

Los Angeles County Department of Public Health

Dear Colleagues and Partners,  

Below are the LACDPH weekly vaccine administration and order updates, upcoming webinars, and newsworthy events. Attached to this email you will find a pdf version of this digest, the slides from 3/29 DPH Office Hours and links.

If you received this email and would like to be added to our listserv, please contact our COVID-19 Provider Vaccine Call Center at covidvaccinereq@ph.lacounty.gov

Table of Contents

·        Page 1: Welcome, Order and Administration Reminders

·        Page 2: CDC Recommendations, UPDATED: Moderna Monovalent Products Expiry Reminder

·        Page 3: Vaccine Marketplace Reminder, Beyond-Use Date (BUD) vs. Expiration Date, Upcoming/Past Meetings, Webinars, Calls and Resources

·        Page 4: LACDPH & CDPH Provider Office Hours Link, Therapeutics

Order and Administration Reminders

  • REMINDER: Please place all orders in myCAvax by the Monday 4/3/23 5pm deadline. Ordering calendar and cadence can be found here.
  • REMINDER: CDPH COVID 19 Provider Call Center will be closed today Friday, March 31st in observance of Cesar Chavez Day. The Cesar Chavez Day holiday ordering cadence can be found here.
  • NOTE: Standard and small order functionality for the monovalent Moderna 12+ and monovalent Moderna (6-11 yrs) vaccine products have been shut-off in myCAvax.
  • NOTE: The current supply of Novavax COVID-19 vaccine 10-dose vial is set to expire on Sunday, April 30, 2023, therefore the CDC has shut off ordering. Novavax is temporarily unavailable for Standard Ordering and remains available for Small Ordering
  • REMINDER: Please report all COVID-19 doses administered within 24 hours to your medical record system and to CAIR as soon as practicable and no later than 72 hours.
  • REMINDER: Record Vaccine Waste in myCAvax. Job aid can be found here.
  • UPDATED: CDPH COVID-19 Provider Operations Manual can be found here.
  • UPDATED: The standard maximum order quantity on myCAvax for Pfizer Bivalent (12+ years, gray cap) single dose vials has increased from 50 doses to 150 doses. The standard minimum order quantity is still 50 doses.
  • Temperature excursion worksheet can be found here.
  • CDPH COVID-19 Vaccine Timing Schedule can be found here.
  • CDC anaphylaxis job aid can be found here.
  • CDC coadministration resources can be found here.
  • COVID-19 Vaccine Product Guide can be found here.
  • CDC Guidance on Vaccine Administration Errors and Deviations can be found here.
  • Vaccine Expiry Checkers:

CDC Recommends Pfizer Infant/Toddler Bivalent Vaccine as Booster for Select Group

  • Children 6 months through 4 years who completed a 3-dose Pfizer Infant/Toddler monovalent primary series are eligible for a booster dose at least two months after completion of their primary series.
  • Pfizer Infant/Toddler bivalent vaccine previously authorized/recommended as third dose of primary series
    • Children who received a primary series of 2 monovalent + 1 bivalent Pfizer Infant/Toddler vaccine are not currently eligible for Pfizer Infant/Toddler vaccine as a booster
  • FDA Press Release from 3/14/23 can be found here.
  • UPDATED 3/16/23: Interim Clinical Consideration can be found here.
  •  Booster Recommendations for Mixed Primary Series:

1

UPDATED: Moderna Monovalent Products Expiry Reminder

LADPH is no longer supporting requests for the monovalent Moderna 6-11 yrs and Moderna 12+ vaccine product as there is no supply and all lots of this product will expire within two weeks. Standard and small order functionality for this product have been shut-off in myCAvax. There are no new safety concerns related to the Moderna monovalent vaccine and product discontinuation is normal as all vaccines have an expiration date. If you demonstrate a need for this product before the impending expiration, please send a message to covidvaccinereq@ph.lacounty.gov and we will continue to search for additional doses though this offer cannot be guaranteed.

IMPORTANT Reminders related to the expiration of the monovalent Moderna 6-11 yrs and monovalent Moderna 12+ vaccine products:

  • Per CDC recommendation, providers should not start a primary series with the Moderna 12+ vaccine product at this time, because the primary series cannot be completed with this product before it expires.
    • All the Moderna 12+ monovalent expires by 4/1/2023. There are no later dated doses. This vaccine product is being sunset.
  • The Moderna updated bivalent vaccine may not be used as a primary series dose at this time, and it is unknown when it will be authorized or recommended.
  • All the Moderna 6-11 yrs monovalent expires between 4/3/2023 and 4/9/2023. There are no later dated doses. This vaccine product is being sunset.
    • This affects everyone 6 years and older who have received the first dose of Moderna for their primary series.
      • They can receive a second dose of Pfizer (if 6 yrs+) or Novavax (if 12yrs+).
  •  
  • CDC guidance allows for mixing of vaccine brands if the original vaccine product is unavailable
  • Guidance on alternative vaccine products that providers can transition to now that Moderna Monovalent vaccines for individuals 12 and up and are no longer available can be found here.

_____________________________________________________________________________________

Vaccine Marketplace Reminder

With products phasing out and expiring, this is a reminder that the Vaccine Marketplace is a great space for all providers to share & request doses of all vaccine types. For those who may need a refresher on what the marketplace is link here  or how to post, there is an interactive provider guide CDPH has released link here

_____________________________________________________________________________________

REMINDER: Beyond-Use Date (BUD) vs. Expiration Date

Expiration Dates:

  • The dates determined by the manufacturer beyond which the vaccine is no longer acceptable to administer to patients, regardless of storage condition.

Beyond-Use Dates (BUD):

  • The last day/time that the COVID-19 vaccine can be safely used after it has been transitioned between storage states (thawed, refrigerated, etc.), or altered (diluted, drawn up for administration, etc.) for patient use.
  • The BUD replaces the manufacturer’s expiration date but never extends it.

Dispose of the vaccine on whichever date/time comes first!

_____________________________________________________________________________________

Upcoming/Past Meetings, Webinars, Calls and Resources

New Quickinar Series: Successful Strategies for Vaccine Management

  • Join CDPH for a new, biweekly quickinar series on successful strategies for COVID-19 vaccine management. Each quickinar is 30 minutes, from 12:00PM-12:30PM. Register here.

Crucial Conversations Webinar:​ Talking with Older Adults about COVID-19 Vaccines and Treatment

  • Wednesday, April 5 at 12:00PM-1:00PM. Register here.

Care Innovations Webinar: Supporting Patients & Providers Through Video Visits

  • Wednesday, April 5th from 12pm-1:30pm. Registration link can be found here

Addressing Vaccine Hesitancy with Patients with Disabilities and their Families

  • Thursday, April 6 at 12:00PM-1:00PM. Register here.

Novavax COVID-19 Vaccine Resources

Pfizer COVID-19 Medical Updates and Trainings

  • Educational resources can be found here.

Moderna COVID-19 Vaccine Resources

  • Educational resources are available on Moderna’s website can be found here

Biweekly myCAvax and MyTurn Office Hours

  • Registration link can be found here

_____________________________________________________________________________________

LACDPH & CDPH Provider Office Hours Link

LA County Department of Public Health Provider Office Hours Information

  • Every other Wednesday from 9am-10am - Next meeting: 04/12/23
    • NOTE: Effective 2/01/23 the Office Hours will be held on a biweekly basis
  • This meeting has been combined with the Mpox Office Hours call. Part one of the meeting will focus on COVID-19 issues while the second part will address Mpox vaccine issues.
  • MS Teams meeting link below; please create a recurring calendar invite with this link.
  • To request meeting slides, please email covidvaccinereq@ph.lacounty.gov

Microsoft Teams meeting

Join on your computer or mobile app

Click here to join the meeting

Or call in (audio only)

+1 323-776-6996,,350547595#   United States, Los Angeles

Phone Conference ID: 350 547 595#

California Department of Public Health Provider Office Hours Registration Link

  • Every Friday from 9am-10:30am.
  • Complete one-time registration here.
  • Meeting recordings and slides can be found here.
  • Providers should add staff names to the Provider Listserv to receive weekly emails and updates. To be added, please email blanca.corona@cdph.ca.gov

_____________________________________________________________________________________

COVID-19 Therapeutics

  • For updated product EUAs, reimbursements, sample prescriptions, patient eligibility checklists, and more, please see our DPH Therapeutics Provider website.
  • UPDATED: Therapeutics Extensions
    • Paxlovid extensions here
    • Lagevrio (Molnupiravir) extensions here
  • Veklury (Remdesivir) providers: To opt-in to ASPR Therapeutics Public Locator, please complete the form linked here
  • Therapeutics Provider Warmline
    • The COVID-19 Therapeutics Warmline is a real-time resource managed by the UCSF National Clinician Consultation Center and is available for all CA health care providers to speak with a pharmacist/clinician.
    • 1-866-268-4322 (COVID-CA) available Monday - Friday, 6am – 5pm or submit an online form to receive free and confidential consultation on COVID-19 testing and treatment.
  • Update on Paxlovid Use in Pregnancy
    • The Society for Maternal-Fetal Medicine states it “supports the use of Paxlovid for treatment of pregnant patients with COVID-19 who meet clinical qualifications.”
    • The American College of Obstetricians and Gynecologists (ACOG) states pregnancy is “among the conditions that put individuals at high risk for clinical progression [to severe COVID]. This makes pregnant patients, including those with pregnancy as their only risk factor, eligible to receive outpatient oral SARS-CoV-2 protease inhibitor therapy [Paxlovid].”